647 filings
Page 14 of 33
8-K
ra1mhpklc25ujt6264xe
20 Feb 19
Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives
12:00am
8-K
bgd 675lrai
29 Nov 18
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
esqvntu
29 Oct 18
Vical Reports Third Quarter 2018 Financial and Operational Results
6:30am
8-K
91zn4xd0fi37ero 3b
7 Aug 18
Vical Reports Second Quarter 2018 Financial and Operational Results
6:35am
EFFECT
y5wks0j
12 Jun 18
Notice of effectiveness
12:15am
8-K
5tcugl8x5ieavdl
11 Jun 18
Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint
12:00am
8-K
d1zh5bmr
7 Jun 18
Departure of Directors or Certain Officers
7:00am
CT ORDER
y60dvkkiozn532z o0a1
6 Jun 18
Confidential treatment order
12:00am
8-K
iqtzqc439q3c
3 May 18
Vical Reports First Quarter 2018 Financial and Operational Results
12:00am
DEFA14A
r4wgtibgjv
9 Apr 18
Additional proxy soliciting materials
12:00am
8-K
9uft9vkgrhpv
15 Mar 18
Vical Reports Fourth Quarter 2017 Financial and Operational Results
12:00am
8-K
32zkk jzon1tiy5
30 Jan 18
Vical Announces Restructuring to Focus Resources on HSV-2 and Antifungal Clinical Programs
12:00am
8-K
s5uoztjk3rt zl1ba2t
22 Jan 18
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
12:00am
424B4
hko3z
9 Nov 17
Prospectus supplement with pricing info
12:00am